← Eichor
Study identifier: NCT05079763 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis

Condition: Acute Radiation Dermatitis  ·  Sponsor: University of the Philippines

PhaseNA
Planned participants54
Who can joinFemale, 18 Years to 80 Years
Healthy volunteersNo

About this study

Acute radiation dermatitis (ARD) is almost universally experienced by patients with cancer during or after radiation therapy. This condition potentially leads to detrimental clinical outcomes as it adversely affects adherence to prescribed subsequent management and further worsens quality of life. Nevertheless, there remains no consensus on the appropriate intervention for ARD. This pilot two parallel-group randomized trial aims to clinically assess the potential of bacterial cellulose-monolaurin hydrogel, compared to placebo cream, to prevent high-grade ARD among Filipinos with breast cancer up to four weeks after last radiotherapy session.

This description comes directly from the study's public registry record.

Talk to the study team

Aedrian A Abrilla, MD  ·  +639363193980  ·  aaabrilla@up.edu.ph

Claudine Yap-Silva, MD  ·  cysilva@up.edu.ph

Always discuss trial participation with your own doctor first.

Locations (1)

Philippine General HospitalManila, PhilippinesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05079763